Table 1. Clinical characteristics of COPD patients included in analyses in figure 1 and 3c.
Data expressed as n(%) or median (IQR) and compared by Fisher’s exact test or Mann Whitney U test. Abbreviations: BODE =score comprising parameters of body Mass index, airflow obstruction, dyspnea and exercise; FEV1 = forced expiratory volume in 1 second; GOLD = Global Initiative for chronic obstructive lung disease; ICS = inhaled corticosteroid
| ICS Users (n=10) | ICS Non Users (n=13) | p value | |
|---|---|---|---|
| Age | 74 (69-78) | 68 (61-69) | 0.013 |
| Male sex | 7 (70%) | 9 (69.2%) | 1.0 |
| GOLD stage I/II/III/IV | 2 (1.8-2) | 2 (1.5-2.5) | 0.91 |
| FEV1 % predicted | 65 (53.0-80.3) | 67 (55.5-78.5) | 0.77 |
| BODE index | 4 (1.0-5.3) | 1 (0.5-3.0) | 0.11 |
| Long term oxygen therapy | 1 (10.0%) | 0 (0%) | 0.43 |
| Body Mass Index | 26.5 (22.9-28.7) | 23.8 (21.9-26.9) | 0.50 |
| Current Smoking | 1 (10%) | 3 (23.1%) | 0.60 |
| Comorbidities | |||
| Diabetes Mellitus | 0 (0%) | 1 (7.7%) | 1.0 |
| Hypertension | 1 (10.0%) | 0 (0%) | 0.43 |
| Ischemic Heart Disease | 2 (20.0%) | 0 (0%) | 0.18 |
| Osteoporosis | 2 (20.0%) | 3 (23.1%) | 1.0 |
| Number of exacerbations in preceding year | 1 (0-3) | 1 (0-1) | 0.53 |
| Treatments | |||
| Fluticasone propionate | 5 (50%) | n/a | - |
| Budesonide | 4 (40%) | n/a | - |
| Beclomethasone dipropionate | 1 (10%) | n/a | - |
| Muscarinic antagonist | 6 (60.0%) | 3 (23.1%) | 0.10 |
| Short or Long-acting Beta2 agonist | 9 (90.0%) | 9 (69.2%) | 0.33 |